Michelle Santos Menezes, Fernanda Valença-Feitosa, Aline Santana Góes, Millena Rakel dos Santos, Laila Santana Silva, Sylmara Nayara Pereira dos Santos, Divaldo Pereira de Lyra Jr, Alfredo Dias de Oliveira Filho
{"title":"High alert medications off the radar: A systematic review","authors":"Michelle Santos Menezes, Fernanda Valença-Feitosa, Aline Santana Góes, Millena Rakel dos Santos, Laila Santana Silva, Sylmara Nayara Pereira dos Santos, Divaldo Pereira de Lyra Jr, Alfredo Dias de Oliveira Filho","doi":"10.1016/j.rcsop.2024.100551","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To identify new drugs that present an increased risk of causing significant damage to critically ill patients due to failure in the administration process.</div></div><div><h3>Method</h3><div>The systematic literature review was conducted in the PubMed, Lilacs, Scopus, Web of Science and gray literature. The year in which the study was conducted was not restricted.</div></div><div><h3>Results</h3><div>The initial search in the databases identified 1477 studies. Fifty manuscripts were selected for evaluation of the full text, at the end of which seven articles were included in this systematic review. As for the characteristic of medication errors, the highest frequency occurred in the administration and prescription phases. In all included studies, incidents with drugs that led to damage were observed. The drugs that are not included in the official lists as High Alert Medications (HAM) that presented an increased risk of causing damage due to medication errors found were: risperidone and piperacycline + tazobactan, in addition to the Infectious Agent class.</div></div><div><h3>Conclusion</h3><div>The results revealed that in fact there are drugs not listed as HAM that, when used in errors, promote greater risks of generating damage in critically ill patients. These described drugs should be considered for inclusion in future official lists of HAM.</div></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"17 ","pages":"Article 100551"},"PeriodicalIF":1.8000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731267/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploratory research in clinical and social pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667276624001483","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To identify new drugs that present an increased risk of causing significant damage to critically ill patients due to failure in the administration process.
Method
The systematic literature review was conducted in the PubMed, Lilacs, Scopus, Web of Science and gray literature. The year in which the study was conducted was not restricted.
Results
The initial search in the databases identified 1477 studies. Fifty manuscripts were selected for evaluation of the full text, at the end of which seven articles were included in this systematic review. As for the characteristic of medication errors, the highest frequency occurred in the administration and prescription phases. In all included studies, incidents with drugs that led to damage were observed. The drugs that are not included in the official lists as High Alert Medications (HAM) that presented an increased risk of causing damage due to medication errors found were: risperidone and piperacycline + tazobactan, in addition to the Infectious Agent class.
Conclusion
The results revealed that in fact there are drugs not listed as HAM that, when used in errors, promote greater risks of generating damage in critically ill patients. These described drugs should be considered for inclusion in future official lists of HAM.
目的:识别由于给药过程失败而增加对危重患者造成重大损害风险的新药。方法:系统查阅PubMed、Lilacs、Scopus、Web of Science和灰色文献。研究进行的年份没有限制。结果:最初在数据库中检索到1477项研究。选择50篇稿件进行全文评估,最后将7篇文章纳入本系统综述。用药差错发生的特点以给药期和处方期发生率最高。在所有纳入的研究中,都观察到药物导致损伤的事件。未列入官方高度警戒药物清单(HAM)的药物,由于药物错误而导致损害风险增加的药物包括:利培酮和哌环素+他唑巴坦,以及感染剂类别。结论:结果表明,事实上存在未列入HAM的药物,当错误使用时,会增加对危重患者造成损害的风险。应考虑将这些描述的药物列入未来的官方有害物质清单。